Viewing Study NCT02178592

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:53 PM
Ignite Modification Date: 2026-01-26 @ 12:34 AM
Study NCT ID: NCT02178592
Status: COMPLETED
Last Update Posted: 2021-01-12
First Post: 2014-06-26
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
Sponsor: ViiV Healthcare
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Infection, Human Immunodeficiency Virus View
None HIV Infections View
Keywords:

Keywords

Keyword Brief Keyword Text View
None integrase inhibitor View
None Mycobacterium tuberculosis View
None rifampicin-sensitive View
None dolutegravir View
None antiretroviral therapy-naïve View
None HIV-1 infection View
None efavirenz View
None co-infection View